271. Ankylosing spondylitis
531 clinical trials,   343 drugs   (DrugBank: 66 drugs),   41 drug target genes,   141 drug target pathways

Searched query = "Ankylosing spondylitis", "Spondylarthritis ankylopoietica"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-005157-29-FR
(EUCTR)
27/04/200713/04/2007EFFET DU METHOTREXATE SUR LA RELATION DOSE - EFFET DE L'INFLIXIMAB DANS LA SPONDYLARTHRITE ANKYLOSANTE - SPAXIMEFFET DU METHOTREXATE SUR LA RELATION DOSE - EFFET DE L'INFLIXIMAB DANS LA SPONDYLARTHRITE ANKYLOSANTE - SPAXIM Les patients seront traités par infliximab, avec ou sans méthotrexate associé, selon la pratique habituelle en accord avec le libellé de l’A.M.M. Seuls le nombre de prélèvements sanguins et de visites diffèreront des modalités thérapeutiques habituelles.
MedDRA version: 9.1;Level: LLT;Classification code 10002556;Term: Ankylosing spondylitis
MedDRA version: 9.1;Level: SOC;Classification code 10028395;Term: Musculoskeletal and connective tissue disorders
Trade Name: Méthotrexate Bellon Comprimé
INN or Proposed INN: METHOTREXATE
Trade Name: REMICADE
INN or Proposed INN: INFLIXIMAB
CHRU-TOURSNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France